enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
De Solidarite Des Travai Fonds also recently made the following trade(s):
- On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The stock was sold at an average price of $15.01, for a total value of $68,670.75.
enGene Stock Down 3.3 %
Shares of ENGN opened at $14.75 on Thursday. enGene Holdings Inc. has a 52-week low of $6.69 and a 52-week high of $43.00. The company has a 50-day moving average of $16.23.
Institutional Inflows and Outflows
Analysts Set New Price Targets
ENGN has been the topic of several recent research reports. Guggenheim began coverage on shares of enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. SVB Leerink initiated coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective for the company. Wells Fargo & Company initiated coverage on enGene in a report on Monday. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, UBS Group assumed coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $34.40.
Check Out Our Latest Analysis on ENGN
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
- Five stocks we like better than enGene
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- High-Yield Texas Instruments Could Hit New Highs Soon
- Buy P&G Now, Before It Sets A New All-Time High
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Transportation Stocks Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.